STAT3 Base Editor for Durable Melanoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers like melanoma and glioblastoma multiforme, which are characterized by aberrant activation of STAT3, are not curative and require repeated dosing, highlighting the need for more effective and durable therapeutic strategies.
Innovation Solution
The use of base editing technology to modify the STAT3 genomic locus using a deaminase and a nucleic acid programmable DNA binding protein, such as Cas9, to generate phosphorylation-deficient STAT3 variants that inhibit STAT3 signaling by reducing or blocking phosphorylation at key sites like Tyr705 and Ser727.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for STAT3-driven cancers are used, then cancer progression can be temporarily controlled, but the treatments require repeated dosing and are not curative
Solution Approach 1:
The base editor is delivered to cells ahead of time to perform permanent genomic modifications to the STAT3 gene. This preliminary genetic editing action creates a durable, long-term inhibition of STAT3 signaling that does not require repeated dosing, unlike temporary inhibitors that need continuous administration.
Solution Approach 2:
The invention changes the fundamental parameter of STAT3 inhibition from temporary pharmacological suppression to permanent genetic modification. By using base editing to create specific nucleotide changes in the STAT3 gene, the therapy achieves lasting suppression of STAT3 activity without the need for repeated treatment cycles.
2Reliability
If base editing is used to modify STAT3 genomic locus, then durable inhibition of STAT3 signaling is achieved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The invention merges multiple functional components into a single base editor complex: a Cas9 nuclease for targeted DNA binding, a deaminase enzyme for base modification, and a guide RNA for target recognition. This integrated approach delivers a sophisticated genomic editing capability in one therapeutic agent, achieving durable STAT3 inhibition despite the inherent complexity of the mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach leads to a significant decrease in active STAT3 protein levels, providing a potentially more durable inhibition of STAT3 signaling and offering a curative alternative to existing therapies.
Implementation Method 1
a deaminase (e.g., a cytidine deaminase or an adenosine deaminase) to treat cancers
Implementation Method 2
a nucleic acid programmable DNA binding protein, such as Cas9
Data Source
AI summary
The disclosure provides adenosine deaminases that are capable of deaminating adenosine in DNA to treat cancers, such as melanoma and glioblastoma. The disclosure also provides fusion proteins, guide RNAs and compositions comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA, for example in a STAT3 gene. In some embodiments, adenosine deaminases provided herein are used to modify the STAT3 gene so that its protein product, STAT3, is unable to be activated. In some embodiments, the methods and compositions provided herein are used to treat melanoma or glioblastoma.